| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5841781 | Life Sciences | 2015 | 37 Pages |
Abstract
The WY14643 and bezafibrate treatments most effectively improved the adverse metabolic and hepatic effects caused by obesity and IR. The results reinforce the central role of PPARalpha, as well as its contrary relationship to PPARgamma in the regulation of metabolic homeostasis and lipolytic pathways in the liver.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sandra Barbosa-da-Silva, Vanessa Souza-Mello, D'Angelo Carlo Magliano, Thatiany de Souza Marinho, Marcia Barbosa Aguila, Carlos Alberto Mandarim-de-Lacerda,